These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 2809215)

  • 1. Nonionic block polymer surfactants enhance the avidity of antibodies in polyclonal antisera against Streptococcus pneumoniae type 3 in normal and Xid mice.
    Van Dam GJ; Verheul AF; Zigterman GJ; De Reuver MJ; Snippe H
    J Immunol; 1989 Nov; 143(9):3049-53. PubMed ID: 2809215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonionic block polymer surfactants modulate the humoral immune response against Streptococcus pneumoniae-derived hexasaccharide-protein conjugates.
    Zigterman GJ; Schotanus K; Ernste EB; Van Dam GJ; Jansze M; Snippe H; Willers JM
    Infect Immun; 1989 Sep; 57(9):2712-8. PubMed ID: 2759707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinct approaches to investigate the importance of the murine 4-1BB 4-1BBL interaction in the antibody response to Streptococcus pneumoniae.
    Moens L; Jeurissen A; Mittler RS; Wuyts G; Michiels G; Boon L; Ceuppens JL; Bossuyt X
    J Leukoc Biol; 2007 Sep; 82(3):638-44. PubMed ID: 17550973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Requirement for B cells for activation of contrasuppressor T cells by type III pneumococcal polysaccharide.
    Braley-Mullen H
    J Immunol; 1990 Apr; 144(7):2465-72. PubMed ID: 2319128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stimulation of liposome-induced humoral immune responses by non-ionic block polymer surfactants in Xid mice.
    Zigterman GJ; Jansze M; Snippe H; Willers JM
    Immunology; 1988 Sep; 65(1):37-42. PubMed ID: 3053425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonionic block polymer surfactants enhance immunogenicity of pneumococcal hexasaccharide-protein vaccines.
    Zigterman GJ; Snippe H; Jansze M; Ernste EB; De Reuver MJ; Willers JM
    Infect Immun; 1988 May; 56(5):1391-3. PubMed ID: 3356469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Avidity and subclasses of IgG after immunization of infants with an 11-valent pneumococcal conjugate vaccine with or without aluminum adjuvant.
    Wuorimaa T; Dagan R; Väkeväinen M; Bailleux F; Haikala R; Yaich M; Eskola J; Käyhty H
    J Infect Dis; 2001 Nov; 184(9):1211-5. PubMed ID: 11598848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of experimental carbohydrate-conjugate vaccines composed of Streptococcus pneumoniae capsular polysaccharides and the universal helper T-lymphocyte epitope (PADRE).
    Alexander J; del Guercio MF; Frame B; Maewal A; Sette A; Nahm MH; Newman MJ
    Vaccine; 2004 Jun; 22(19):2362-7. PubMed ID: 15193395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Avidity of the immunoglobulin G response to a Neisseria meningitidis group C polysaccharide conjugate vaccine as measured by inhibition and chaotropic enzyme-linked immunosorbent assays.
    Harris SL; Tsao H; Ashton L; Goldblatt D; Fernsten P
    Clin Vaccine Immunol; 2007 Apr; 14(4):397-403. PubMed ID: 17287312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IL-12 enhances antibody responses to T-independent polysaccharide vaccines in the absence of T and NK cells.
    Buchanan RM; Arulanandam BP; Metzger DW
    J Immunol; 1998 Nov; 161(10):5525-33. PubMed ID: 9820529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Requirements for activation of contrasuppressor T cells by type III pneumococcal polysaccharide.
    Braley-Mullen H
    J Immunol; 1986 Jan; 136(2):396-401. PubMed ID: 2867113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Avidity maturation, repertoire shift, and strain differences in antibodies to bacterial levan, a type 2 thymus-independent polysaccharide antigen.
    Boswell CM; Stein KE
    J Immunol; 1996 Sep; 157(5):1996-2005. PubMed ID: 8757320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct demonstration of specific suppressor T cells in the mice tolerant to type III pneumococcal polysaccharide: two-step requirement for development of detectable suppressor cells.
    Braley-Mullen H
    J Immunol; 1980 Oct; 125(4):1849-54. PubMed ID: 6157748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenic properties in mice of hexasaccharide from the capsular polysaccharide of Streptococcus pneumoniae type 3.
    Snippe H; van Houte AJ; van Dam JE; De Reuver MJ; Jansze M; Willers JM
    Infect Immun; 1983 Jun; 40(3):856-61. PubMed ID: 6852923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular dissection of antibody responses against pneumococcal surface protein A: evidence for diverse DH-less heavy chain gene usage and avidity maturation.
    Rohatgi S; Dutta D; Tahir S; Sehgal D
    J Immunol; 2009 May; 182(9):5570-85. PubMed ID: 19380805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimation of the avidity of antibodies in polyclonal antisera against Streptococcus pneumoniae type 3 by inhibition ELISA.
    van Dam GJ; Verheul AF; Zigterman GJ; de Reuver MJ; Snippe H
    Mol Immunol; 1989 Mar; 26(3):269-74. PubMed ID: 2704374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced protection against pneumococcal infection elicited by immunization with the combination of PspA, PspC, and ClpP.
    Cao J; Chen D; Xu W; Chen T; Xu S; Luo J; Zhao Q; Liu B; Wang D; Zhang X; Shan Y; Yin Y
    Vaccine; 2007 Jun; 25(27):4996-5005. PubMed ID: 17524530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduction in functional antibody activity against Streptococcus pneumoniae in vaccinated elderly individuals highly correlates with decreased IgG antibody avidity.
    Romero-Steiner S; Musher DM; Cetron MS; Pais LB; Groover JE; Fiore AE; Plikaytis BD; Carlone GM
    Clin Infect Dis; 1999 Aug; 29(2):281-8. PubMed ID: 10476727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human monoclonal antibodies specific for capsular polysaccharides of Klebsiella recognize clusters of multiple serotypes.
    Lang AB; Bruderer U; Senyk G; Pitt TL; Larrick JW; Cryz SJ
    J Immunol; 1991 May; 146(9):3160-4. PubMed ID: 2016541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of 5-valent conjugate pneumococcal protein A - Capsular polysaccharide pneumococcal vaccine against invasive pneumococcal disease.
    Meng C; Lin H; Huang J; Wang H; Cai Q; Fang L; Guo Y
    Microb Pathog; 2009 Sep; 47(3):151-6. PubMed ID: 19467319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.